

## Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

The article entitled, "Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90," which was published in the August 15, 2011, issue of *Clinical Cancer Research* (1), is being retracted at the request of Pfizer, the study sponsor.

In early 2016, the *CCR* editorial office became aware of potential image manipulation in the article through a record posted on pubpeer.com. The *CCR* editorial office contacted the corresponding author about the matter and received a response from a Pfizer representative, who informed us that the company assembled a review team to investigate the matter further. A Pfizer representative recently contacted the *CCR* editorial office with the results of the investigation: Most or all of the images in question appear to be duplications, and most of the authentic, original images that should have been used in place of the duplicated images cannot be located. As a result, Pfizer is requesting retraction of the article and has obtained consent from all six authors.

The matter was reviewed by members of the AACR Publications staff and the *CCR* editors, who agree that the figure manipulation present in the article merits retraction. Five authors have consented to this retraction notice; the *CCR* editorial office did not receive a response from Dr. Pramod P. Mehta.

### Reference

1. Mehta PP, Whalen P, Baxi SM, Kung P-P, Yamazaki S, Yin M-J. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. *Clin Cancer Res* 2011;17:5432-42.

---

Published online January 16, 2017.

doi: 10.1158/1078-0432.CCR-16-2872

©2017 American Association for Cancer Research.

# Clinical Cancer Research

## Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

*Clin Cancer Res* 2017;23:612.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/23/2/612>

**Cited articles** This article cites 1 articles, 1 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/23/2/612.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/2/612>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.